The perfect team
James W. Crow, PhD | CEO
Dr. Crow has a long and distinguished career in the pharmaceutical industry, spanning nearly 35 years. Jim spent many years at Burroughs Wellcome, where he held various positions including Section Head/Associate Medical Director. In addition to his management duties at Burroughs Wellcome, he lead numerous cross-divisional, international projects from preclinical, Pre-IND, through the Clinical Phases of Development and subsequent regulatory review process. One highlight of tenure was his leadership of the epoprostenol program, a drug targeting an unmet medical need. Jim successfully led this complex development, and epoprostenol (Flolan) became the first treatment approved to treat severely ill patients with Pulmonary Arterial Hypertension. This breakthrough medicine saved and extended many lives.
Dr. Crow then co-founded United Therapeutics, where he served as President and Chief Operating Officer and focused on raising capital, assessing prospective intellectual property and building a development team. He successfully in-licensed an early stage product that was sitting on the shelf at Glaxo and helped oversee the rapid international development of this product (treprostinil, Remodulin), which gained FDA approval in only four years. Today, United Therapeutics has a market cap of over 3.4 billion dollars.
Jim is co-founder and Chief Executive Officer of ACRIS Pharmaceuticals. He has a PhD in Pharmacology from the University of Mississippi Medical Center, and additional post-graduate/fellowship training in Mathematics and Pharmacokinteics from The University of North Carolina at Chapel Hill and State University of New York, Buffalo.
David Mottola, PhD | President & COO
Dr. Mottola has over 21 years of experience in the pharmaceutical industry with expertise in drug development and strategic planning. He started his career in Clinical Sciences at Burroughs Wellcome, later Glaxo Wellcome, and then moved to Bausch and Lomb Pharmaceuticals to help start and manage a new functional area and department - Clinical Development. David then joined a small start-up biotech company, United Therapeutics, where he spent 11 years in various positions of increasing responsibility and leadership, concluding as Senior VP - Clinical Operations, Clinical Quality and Standards, and Preclinical Sciences. He was instrumental in the success of this start-up company and in growing it into a mid-size organization with revenues exceeding $700 million. David subsequently was promoted to Executive VP - Research and Clinical Development at Lung LLC (a subsidiary of United Therapeutics) to oversee all of their R&D activities.
Over his career, he has led all key functional areas of pharmaceutical development, including Clinical, Regulatory, Preclinical, CMC, Statistics, etc. And, David has been intimately involved in numerous drug development programs and in multiple drug approvals.
At ACRIS, he rejoins his colleague Dr. Jim Crow, whom he previously worked with at Burroughs Wellcome and United Therapeutics, to bring their successful track records together. David has a BS in Biology and a PhD in Pharmacology from the University of North Carolina, Chapel Hill.
In addition to the founders, ACRIS utilizes a network of consultants and advisors, with proven history of success, to facilitate and enhance its operations. These strategic relationships include Legal, Business and Finance, as well as various drug development specialists. ACRIS is located in the LAUNCH Chapel Hill incubator space (Chapel Hill, NC), which provides additional resources, support and training for ACRIS and other start-up ventures.